Kenjin Pharmaceutical Injection Boronzomi to be included in priority review

Medical Network May 14 hearing May 12, CDE official website shows, and health into drug for injection bortezomib to be included in the priority review, included the reason for the "same production line, was in 2020 in the United States to apply for the domestic market" Meters within the network data show that in 2018 Chinese public medical institutions terminal bortezomib sales of 1.442 billion yuanCurrently injection bortezomib No business is too assessment, pharmaceutical and health into a new Classified newspaper production, if successful will be deemed approved by the consistency of evaluationpriority to be included in the review of the pharmaceutical and health into publicestablished in 2006, is located in Chengdu Hi-tech comprehensive Free Trade Zone, it is the only continuous period of seven years passed five consecutive USfood Administration (FDA) on-site inspection (by 2019 is an overall zero defects), high-quality QP examination by the European Union, and continuous sterile injectablesold in the US for six yearsBortezomib is a protease inhibitor, is a novel anti-cancer drug targeted therapy, for the treatment of multiple myeloma and mantle cell lymphoma, have rapid onset of security high (it can be used in patients with renal insufficiency and even renal failure) advantagemeters within the network data show that China's urban public2019 years, the county-level public hospitals, urban community centers and township hospitals (referred to as the Chinese public medical institutions) terminal for injection bortezomib sales 14.42 billion yuan, up 6.21 percentChinese public medical institutions terminal bortezomib sales (unit: million)domestic market seven pharmaceutical companies (the original research +6 domestic enterprises) have injected production approval of bortezomib with boron2019 manufacturers the competitive landscape of public medical institutions terminal in China, Xian-Janssen with 63.75% market share ranked first, Chia Tai Pharmaceutical Group accounted for 14.32 percent of market share, accounting for 13.8% Stockhausen medicineChinese public medical institutions terminal manufacturers to bortezomib, boron, 2019competition withinrice network conformance assessment database, the current injection bortezomib No company had to commentPharmaceutical and health into bortezomib for injection of drugs by listing application submitted to the new Class 4, after the inclusion in the priority review and approved through the assessment schedule will be accelerated Source: CDE, the network database m